<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Rifabutin: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int200-rifabutin.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int200-rifabutin.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int200-rifabutin.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int127-antibacterials.htm">Antibacterials</a> &gt; <a href="bnf_int199-rifamycins.htm">Rifamycins</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int199-rifamycins.htm" title="Previous: Rifamycins">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int201-rifampicin.htm" title="Next: Rifampicin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Rifabutin</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Rifabutin</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>possibly increased by</span> <span>triazoles</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>atazanavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span>avoidance of concomitant </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>atovaquone</span> <span>(plasma concentration of both drugs reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int167-azithromycin.htm">Azithromycin</a></td><td class="cAI"><p><span>increased risk of side-effects including neutropenia when </span> <span>rifabutin</span> <span>given with</span> <span>azithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of  </span> <span>rifabutin</span> <span>increased by</span> <span>clarithromycin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>darunavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>rifabutin</span> <span>reduced by</span> <span>efavirenz</span> <span>—increase dose of <span>rifabutin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>possibly increased by</span> <span>erythromycin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span> <span>rifabutin</span> <span>given with</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>fluconazole</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>fosamprenavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>indinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>itraconazole</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>nelfinavir</span> <span>(halve dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>rifabutin</span> <span>possibly increased by</span> <span>nevirapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>posaconazole</span> <span>(also plasma concentration of <span>posaconazole</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>rilpivirine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of  </span> <span>rifabutin</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>saquinavir</span> <span>(also plasma concentration of <span>saquinavir</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>tipranavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>voriconazole</span> <span>, also <span>rifabutin</span> reduces plasma concentration of <span>voriconazole</span> (increase dose of <span>voriconazole</span> and also monitor for <span>rifabutin</span> toxicity)</span>  </p></td><td></td></tr></tbody></table><p><strong>Rifabutin</strong> belongs to <strong>Rifamycins</strong> and will have the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span></span> <span>rifamycins</span> <span>reduce plasma concentration of</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>corticosteroids</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>coumarins</span> <span>(reduced anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int161-dapsone.htm">Dapsone</a></td><td><p><span></span> <span>rifamycins</span> <span>reduce plasma concentration of</span> <span>dapsone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>disopyramide</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>possibly accelerate metabolism of</span> <span>sulfonylureas</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int275-tolbutamide.htm">Tolbutamide</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>tolbutamide</span> <span>(reduced effect)</span>  </p></td><td></td></tr></tbody></table><p><strong>Rifabutin</strong> belongs to <strong>Antibacterials</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1058-typhoid-vaccine-oral.htm">Typhoid Vaccine (oral)</a></td><td><p><span></span> <span>antibacterials</span> <span>inactivate</span> <span>oral typhoid vaccine</span> <span>—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="PHP8409-typhoid-vaccines.htm">section 14.4</a></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int199-rifamycins.htm">Previous: Rifamycins</a> | <a class="top" href="bnf_int200-rifabutin.htm#">Top</a> | <a accesskey="]" href="bnf_int201-rifampicin.htm">Next: Rifampicin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>